The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene, Johnson & Johnson and Roche, and supported through educational grants from Bristol Myers Squibb, Incyte, Lilly, and Pfizer. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View lym content recommended for you
Michael Dickinson
Executive Steering Committee Member
Doctor Michael Dickinson is a clinical hematologist at the Peter MacCallum Cancer Centre, Melbourne, AU, and is the Lead of the Aggressive Lymphoma Stream within the Integrated Haematology Service. Dr Dickinson obtained his medical degree at the University of Western Australia, Perth, AU, and trained as a physician in Brisbane, AU, and London, UK. He is a Julie Borschmann Fellow of Myeloma Research, University of Melbourne, Melbourne, AU.
Dr Dickinson’s research areas of interest include aggressive lymphoma, myelodysplastic syndromes, acute myeloid leukemia, and myeloma. He is a Principal Investigator in phase I/II studies, mainly in aggressive lymphoma. His research focuses on the role of epigenetic modifiers and immunotherapies in hematological malignancies and the use of eltrombopag as a supportive care agent in myeloid malignancies. Additionally, he researches novel methods of molecular analysis for patients with lymphoid malignancies.
Positions of responsibility/awards:
- Awarded the Julie Borschmann Fellow of Myeloma Research at the University of Melbourne in 2013
- Member of the Victorian Epigenetics Group
- Member of the Aggressive Lymphoma and Leukaemia Committees of the Australasian Leukaemia and Lymphoma Group (ALLG) and Lymphoma Australia
- Member of the Haematology Society of Australia and New Zealand (HSANZ)
- Member of the American Society of Hematology
Filter by content: